Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary breast lymphoma: A single center study.

Na Zhang1, Caineng Cao1, Yuan Zhu1

  • 1Department of Radiation Oncology, Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.

Oncology Letters
|March 31, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metformin attenuates lens epithelial cell senescence by suppressing cGAS-STING via SIRT1-PGC-1α-mediated mitochondrial fission.

Experimental gerontology·2026
Same author

Flavokawain A Targets CXCR4-Mediated Vasculogenic Mimicry to Reverse Hepatocellular Carcinoma Resistance to Tyrosine Kinase Inhibitors.

Phytotherapy research : PTR·2026
Same author

Staging of non-metastatic nasopharyngeal carcinoma with PET/CT.

European radiology·2026
Same author

De-Escalation Strategies in Nasopharyngeal Carcinoma.

Current oncology reports·2026
Same author

Comparison of the eighth and ninth editions of American Joint Committee on Cancer/Union for International Cancer Control staging for non-metastatic nasopharyngeal carcinoma.

Otolaryngologia polska = The Polish otolaryngology·2026
Same author

Clinical feasibility test of 60 kVp double-low-dose coronary CT angiography with a deep learning reconstruction algorithm.

Insights into imaging·2026
Same journal

SUMOylation inhibitor TAK-981 suppresses proliferation and induces apoptosis in SK-UT-1B uterine leiomyosarcoma cells.

Oncology letters·2026
Same journal

Androgen receptor drives lenvatinib resistance in hepatocellular carcinoma through transcriptional activation of EIF3I and a downstream ceRNA axis.

Oncology letters·2026
Same journal

FBXL5 depletion as a novel strategy against osteosarcoma: Evidence for MEK/ERK inhibition and enhanced therapeutic sensitivity.

Oncology letters·2026
Same journal

[Expression of Concern] Myricetin inhibits migration and invasion of hepatocellular carcinoma MHCC97H cell line by inhibiting the EMT process.

Oncology letters·2026
Same journal

Identification of neoadjuvant chemoradiotherapy resistance-associated proteins in locally advanced rectal cancer: A pilot study.

Oncology letters·2026
Same journal

Overexpression of EZH2 is associated with clinicopathological parameters and poor prognosis in gliomas.

Oncology letters·2026
See all related articles

Primary breast lymphoma (PBL) is rare but shows a good prognosis with effective management. This study found a 5-year survival rate of over 74%, indicating favorable outcomes for most patients.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Medicine

Background:

  • Primary breast lymphoma (PBL) is an uncommon malignancy.
  • Understanding its clinical features and treatment outcomes is crucial for patient care.

Purpose of the Study:

  • To summarize the clinical characteristics of primary breast lymphoma.
  • To evaluate the management approaches and survival outcomes for PBL patients.

Main Methods:

  • Retrospective analysis of 29 newly diagnosed PBL patients treated between April 2006 and May 2013.
  • Median follow-up of 66.8 months.
  • Kaplan-Meier survival analysis was used to estimate overall and progression-free survival rates.

Main Results:

  • The 5-year overall survival and progression-free survival rates were 74.4% and 74.6%, respectively.
Keywords:
diffuse large B cell lymphomaprimary breast lymphomaprognosistreatment

Related Experiment Videos

  • 22 out of 29 patients were lymphoma-free at follow-up.
  • A low incidence of local relapse was observed, with only 5 patients experiencing recurrence at various sites.

    • Conclusions:

    • Primary breast lymphoma is a rare entity with a generally good prognosis.
    • Current management strategies, including chemotherapy, appear effective in achieving long-term remission for most patients.
    • Further research is needed to develop treatments for chemotherapy-resistant cases.